Human Respiratory Syncytial Virus (RSV) Kreatives Layout mit 3D Renderings des Respiratory Syncytial Virus (RSV), ein verbreitetes ansteckendes Virus, das die menschlichen Atemwege infiziert. Kredit: NIAID
5120 x 3468 px | 43,3 x 29,4 cm | 17,1 x 11,6 inches | 300dpi
Aufnahmedatum:
20. September 2022
Ort:
US
Weitere Informationen:
Dieses Bild ist ein gemeinfreies Bild. Dies bedeutet, dass entweder das Urheberrecht dafür abgelaufen ist oder der Inhaber des Bildes auf sein Urheberrecht verzichtet hat. Alamy berechnet Ihnen eine Gebühr für den Zugriff auf die hochauflösende Kopie des Bildes.
Dieses Bild kann kleinere Mängel aufweisen, da es sich um ein historisches Bild oder ein Reportagebild handel
Respiratory syncytial virus (RSV), [a] also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a common, contagious virus that causes infections of the respiratory tract. It is a negative-sense, single-stranded RNA virus. Its name is derived from the large cells known as syncytia that form when infected cells fuse. RSV is the single most common cause of respiratory hospitalization in infants, and reinfection remains common in later life: it is a notable pathogen in all age groups. Infection rates are typically higher during the cold winter months, causing bronchiolitis in infants, common colds in adults, and more serious respiratory illnesses such as pneumonia in the elderly and immunocompromised. RSV can cause outbreaks both in the community and in hospital settings. Following initial infection via the eyes or nose, the virus infects the epithelial cells of the upper and lower airway, causing inflammation, cell damage, and airway obstruction.[2] A variety of methods are available for viral detection and diagnosis of RSV including antigen testing, molecular testing, and viral culture. The main prevention measures include hand-washing and avoiding close contact with infected individuals.[5] In May 2023, the US Food and Drug Administration (FDA) approved the first RSV vaccine, Arexvy (developed by GSK plc), for adults aged 60 and older. The prophylactic use of palivizumab or nirsevimab can prevent RSV infection in high-risk infants. Treatment for severe illness is primarily supportive, including oxygen therapy and more advanced breathing support with CPAP or nasal high flow oxygen, as required. In cases of severe respiratory failure, intubation and mechanical ventilation may be required. Ribavirin is the only antiviral medication licensed for the treatment of RSV in children, although its use remains controversial.
